New combo therapy aims to save rectums from surgery in rectal cancer trial

NCT ID NCT06204094

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a new approach for people with a certain type of locally advanced rectal cancer. The treatment combines short-course radiation (sparing lymph nodes), two chemotherapy drugs (capecitabine and oxaliplatin), and an immunotherapy drug (sintilimab). The goal is to see if this combination can make the cancer disappear completely, allowing some patients to avoid surgery and keep their rectum. The study plans to enroll 37 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Sintilimab (a type of immunotherapy), capecitabine (chemotherapy), oxaliplatin (chemotherapy), and short-course radiation
What this could lead to
If successful, this approach could help more people with rectal cancer avoid major surgery and preserve their rectum, while still effectively treating the cancer.
What could go wrong
This is a small, early-phase trial with only 37 participants, so results may not apply to everyone. The combination of treatments may cause significant side effects, and the cancer could still return.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhejiang University Affiliated Jinhua Hospital

    RECRUITING

    Jinhua, Zhejiang, 0579, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.